U.S. M&A volume may be at the lowest level since early 2003, but  technology deals are on a tear more »

In introducing biotech guru G. Steven Burrill today, Illinois BIO (iBIO) president David Miller likened the speaker to the Michael Jordan of biotechnology. “There will never be the next Steven Burrill,” he said. “At a critical time in biotech’s development, he was there.” more »

Partnering buoyant with numerous bigpharma deals annnounced in the past week. M&A also saw several billion dollar deals more »

This month we are providing you with an overview of deal making activity in the life sciences, covering partnering and M&A in April 2012 more »

With U.S. biomedical research under assault by everyone from patients to Congress for turning so few scientific discoveries into treatments, a leading finance expert says decisions about what studies to bankroll should be made the same way pension funds, mutual funds, and university endowments decide how to invest their money more »

For four years Chris Viehbacher has been bracing himself for a nasty turn more »

Congress appears poised this year to deliver on years of lobbying by industry to speed up reviews of new drugs and cut regulatory red tape more »

A recent study (report: Royalty Financing Terms and Agreements) has shown a significant increase in the use of royalty and revenues based financing as an alternative way for biotechs to raise finance more »

M&A dominates the week as Nestle snaps up Pfizer nutritions business, Watson acquires Actavis, and AstraZeneca acquires Ardea more »

Partnering gains momentum whilst M&A slows significantly more »